COVID-19 and Influenza Testing at 10 Days Post-Symptom Onset

Test Performance Considerations

Antigen test sensitivity drops substantially after 5 days of symptoms, with pooled sensitivity of only 80% (95% CI: 74-86%) when testing occurs more than 5 days after symptom onset, compared to 89% (95% CI: 83-93%) within the first 5 days 1, 2, 3.
Molecular NAAT testing remains more sensitive than antigen testing at this timepoint, though viral loads are typically declining 4, 5.
The optimal window for COVID-19 testing is within the first 5 days of symptom onset when viral loads are highest and test sensitivity is maximized 2, 3.

Most patients are no longer infectious by day 10 after symptom onset in mild-to-moderate COVID-19 cases 6, 7.
The CDC and WHO recommend 10 days of isolation for mild-to-moderate disease because replication-competent virus is rarely cultured beyond this timepoint 6, 7.
Important exception: Severely ill or severely immunocompromised patients may remain infectious for 15-20 days after symptom onset 6, 7.

A positive test at day 10 does not necessarily indicate ongoing infectiousness, as PCR tests can detect non-viable viral RNA fragments for up to 30 days after infection 7.
If the patient has ongoing symptoms AND a positive test at day 10, this combination suggests potential continued viral replication and warrants extended isolation precautions 7.
Testing at day 10 is not routinely recommended unless there are new or worsening symptoms without alternative explanation, or specific clinical/epidemiologic reasons exist 4, 5.

Consider testing if: Patient has new or worsening symptoms without alternative explanation 4, 5.
Consider testing if: Patient is severely immunocompromised (may have prolonged viral shedding) 6, 7.
Consider testing if: Patient had severe/critical illness requiring hospitalization 6, 7.
Consider testing if: Testing is needed for infection control purposes (e.g., healthcare worker clearance, outbreak investigation) 7.

For COVID-19: Use molecular NAAT rather than antigen testing at this late timepoint if testing is deemed necessary, as sensitivity is higher 4, 5, 2.
PCR positivity does not equal infectivity beyond day 10 in most cases—interpret positive results in clinical context with symptom status 7.
For severely immunocompromised patients, specialist consultation may be needed to determine appropriate isolation duration regardless of test results 6.

In patients who develop new or worsening respiratory or systemic symptoms around 30 days after the initial illness, repeat SARS‑CoV‑2 testing can be contemplated to evaluate a possible new infection rather than persistence of the original disease. (IDSA guidance) 8, 9
The IDSA notes that repeat testing is appropriate when symptoms persist or worsen only during the acute window (≤ 5 days from onset); applying this recommendation at 30 days is not supported. (IDSA guidance) 8, 9
If symptoms at 30 days are clearly distinct from the original presentation, clinicians should consider reinfection or an alternative diagnosis and obtain fresh diagnostic work‑up rather than relying on repeat viral testing. (IDSA guidance) 8, 9

The IDSA panel advises against using nucleic‑acid amplification tests (NAAT) to determine when to end isolation after day 10, as PCR positivity at this stage reflects non‑viable viral RNA and does not correlate with contagiousness. (IDSA guidance) 8, 9